Related Experiment Video
Updated: Dec 11, 2025

Exploring the Arginine Methylome by Nuclear Magnetic Resonance Spectroscopy
Published on: December 16, 2021
Systems level profiling of arginine starvation reveals MYC and ERK adaptive metabolic reprogramming
Caitlyn B Brashears1, Meltem Barlin1, William R Ehrhardt1
1Department of Medicine, Washington University in Saint Louis School of Medicine, St. Louis, MO, 63110, USA.
Abstract:
Arginine auxotrophy due to the silencing of argininosuccinate synthetase 1 (ASS1) occurs in many carcinomas and in the majority of sarcomas. Arginine deiminase (ADI-PEG20) therapy exploits this metabolic vulnerability by depleting extracellular arginine, causing arginine starvation. ASS1-negative cells develop resistance to ADI-PEG20 through a metabolic adaptation that includes re-expressing ASS1. As arginine-based multiagent therapies are being developed, further characterization of the changes induced by arginine starvation is needed. In order to develop a systems-level understanding of these changes, activity-based proteomic profiling (ABPP) and phosphoproteomic profiling were performed before and after ADI-PEG20 treatment in ADI-PEG20-sensitive and resistant sarcoma cells. When integrated with metabolomic profiling, this multi-omic analysis reveals that cellular response to arginine starvation is mediated by adaptive ERK signaling and activation of the Myc-Max transcriptional network. Concomitantly, these data elucidate proteomic changes that facilitate oxaloacetate production by enhancing glutamine and pyruvate anaplerosis and altering lipid metabolism to recycle citrate for oxidative glutaminolysis. Based on the complexity of metabolic and cellular signaling interactions, these multi-omic approaches could provide valuable tools for evaluating response to metabolically targeted therapies.
Insights
Arginine starvation therapy resistance in cancer cells involves adaptive ERK signaling and Myc-Max network activation. This study reveals metabolic shifts enhancing oxaloacetate production and glutaminolysis, crucial for understanding treatment response.
Area of Science:
- Metabolic pathways
- Cancer biology
- Proteomics
Background:
- Arginine auxotrophy, caused by argininosuccinate synthetase 1 (ASS1) silencing, is common in carcinomas and sarcomas.
- Arginine deiminase (ADI-PEG20) therapy targets this by depleting extracellular arginine, inducing starvation.
- Resistance to ADI-PEG20 emerges through metabolic adaptation, including ASS1 re-expression.
Purpose of the Study:
- To understand the systemic changes induced by arginine starvation in cancer cells.
- To characterize the adaptive mechanisms of ADI-PEG20-resistant sarcoma cells.
- To explore multi-omic approaches for evaluating metabolically targeted therapies.
Main Methods:
- Activity-based proteomic profiling (ABPP) before and after ADI-PEG20 treatment.
- Phosphoproteomic profiling in sensitive and resistant sarcoma cells.
- Integration of proteomic data with metabolomic profiling.
Main Results:
- Arginine starvation response is mediated by adaptive ERK signaling and Myc-Max transcriptional network activation.
- Proteomic changes facilitate oxaloacetate production via enhanced glutamine and pyruvate anaplerosis.
- Altered lipid metabolism recycles citrate for oxidative glutaminolysis.
Conclusions:
- Multi-omic analysis provides a systems-level understanding of cellular response to arginine starvation.
- Adaptive signaling and metabolic reprogramming are key to resistance mechanisms.
- These integrated approaches can evaluate responses to arginine-targeted cancer therapies.
More Related Videos
08:04Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method
Published on: October 23, 2018
08:03A Tandem Liquid Chromatography–Mass Spectrometry-based Approach for Metabolite Analysis of Staphylococcus aureus
Published on: March 28, 2017
Related Concept Videos
Stringent Response in E. coli
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Global Regulatory Systems
PI3K/mTOR/AKT Signaling Pathway